Abstract
Imaging of metastatic castrate-resistant prostate cancer to select patients suitable for peptide receptor radioligand therapy can be performed with both SPECT and PET PSMA radiotracers. Although PET radiotracers generally have higher sensitivity and spatial resolution, SPECT tracers can be an effective alternative when PET/CT systems are unavailable in the clinical setting. We present a case of a 43-year-old male, who was referred to our facility for workup for radioligand PSMA therapy. His Tc-99m PSMA images revealed diffuse bone infiltration in a pattern mimicking a bone scan.
Data Availability
Contact the corresponding author for data requests.
References
Dias AH, Bouchelouche K. Skeletal "Superscan" on 18F-choline PET/CT: cases of myeloproliferative disease. Clin Nucl Med. 2016;41:173–4.
Sager S, Akgun E, Aahin OE, Akgun B, Sonmezoglu K. Superscan Imaging on Ga-68 PSMA PET/CT in prostate cancer patient. J Nucl Med Radiat Ther. 2017;8:1.
Mokoala K, Lawal I, Lengana T, Kgatle M, Giesel FL, Vorster M, et al. PSMA theranostics: science and practice. Cancers. 2021;13:3904.
Su HY, Liu RS, Liao SQ, Wang SJ. F-18 FDG PET superscan. Clin Nucl Med. 2006;31:28–9.
Cheng G, Alavi A, Lim EH, Akers S. Superscan-like hypermetabolic lesions on delayed FDG PET/CT imaging in a patient with lung cancer. Clin Nucl Med. 2012;37:912–3.
Kim DW, Kim CG, Park SA, Jung SA, Yang SH. Metabolic super scan in F-FDG PET/CT imaging. J Korean Med Sci. 2010;25:1256–67.
Bailly M, Besse H, Kerdraon R, Metrard G, Gauvain S. 18F-FDG PET/CT superscan in prostate cancer. Clin Nucl Med. 2014;39:912–4.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.
Acknowledgements
With their permission, the authors would like to acknowledge all the nuclear medicine radiographers, at the department of nuclear medicine, University f The Free State.
Author Information
Dr Evbuomwan Osayande is a nuclear medicine specialist and a senior lecturer.
Dr Fourie Carika is a nuclear medicine specialist and a senior lecturer.
Engelbrecht Gerrit is a nuclear medicine consultant and head of department.
Funding
There is no source of funding.
Author information
Authors and Affiliations
Contributions
The study was designed by Evbuomwan Osayande. Material preparation and data collection were performed by Evbuomwan Osayande, Fourie Carika and Engelbrecht Gerrit. The first draft of the manuscript was written by Evbuomwan Osayande, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing Interest
Evbuomwan Osayande, Fourie Carika, and Engelbrecht Gerrit declare that they have no competing interests.
Ethics Approval and Consent to Participate
The study was approved by the institutional review board from the University of The Free State Health Sciences Research Ethics Committee (UFS-HSD2021/0889/2501), and informed consent was obtained from all individual participants included in the study (or the requirement for written consent was waived by the institutional review board). All procedures performed in studies involving human participants were in accordance with the Helsinki declaration as revised in 2013 and its later amendments.
Consent for Publication
The participants signed consent regarding publishing their data.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Osayande, E., Carika, F. & Gerrit, E. Technetium 99m PSMA Superscan Mimicking a Bone Scan Gone Wrong. Nucl Med Mol Imaging 56, 211–217 (2022). https://doi.org/10.1007/s13139-022-00749-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-022-00749-3